Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.
about
Pathobiology of Paget's Disease of BoneFunctional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cellsA receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.Giant cell tumor in a case of Paget's disease of bone: an aggressive benign tumor exhibiting a quick response to an innovative therapeutic agent.Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease.Osteosarcoma in Paget's disease of bone.Emerging strategies and therapies for treatment of Paget's disease of bone.Zoledronic acid (Zometa) use in bone disease.Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.Paget disease of bone.Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and ManagementMeasles virus nucleocapsid protein increases osteoblast differentiation in Paget's diseaseExperimental models of Paget's disease.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.The molecular pathogenesis of Paget disease of bone.A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironmentIncreased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice.FGF-2 stimulation of RANK ligand expression in Paget's disease of boneDACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells.Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity.Gene expression profile in osteoclasts from patients with Paget's disease of bone.The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts.Dickkopf-1 as a potential therapeutic target in Paget's disease of bone.c-FMS inhibitors: a patent review.Bisphosphonates: effects on osteoblast.Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene.Biology and Treatment of Paget's Disease of Bone.CXCL5 stimulation of RANK ligand expression in Paget's disease of bone.Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.Remarkable effect of 2[small alpha]-modification on the VDR antagonistic activity of 1small alpha-hydroxyvitamin D3-26,23-lactones.Autophagy and 3-Phosphoinositide-Dependent Kinase 1 (PDK1)-Related Kinome in Pagetic Osteoclasts.Transforming growth factor-beta induces expression of receptor activator of NF-kappa B ligand in vascular endothelial cells derived from bone.Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in paget's disease of bone.Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss.Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis.Markers of bone metabolism in eugonadal female patients with beta-thalassemia major.
P2860
Q26824476-9219F2B2-0B8F-4CA6-8CB6-31E1A487947CQ28236662-EF9ED2CB-8613-48EF-B085-25B0AA69A585Q33594667-5195E33E-B6D9-424F-BA02-7A0F099D0E03Q34086847-3E92AD1A-C4D8-420F-A8F3-A897EFA9AAA5Q34417248-535298C5-EDFB-426E-B251-2BF81D034626Q34512953-0C06A0D6-CA38-4B9D-B205-43EA4DBE77C9Q34574123-A00D86AB-3E5E-420B-8D87-DFB19CFF8F7DQ34987305-C3BAE8CA-C52F-49FE-B06B-AF0CB94BAD70Q35117725-876D5107-2974-4C61-9572-2F9DB8CEDF80Q35659971-31259802-95B5-410D-9B5A-D9B8B43FBD97Q36029217-1690872A-0F98-461A-B8DD-8894CC9C0266Q36059397-DB04DAB7-401D-44D1-82CD-15188F04D1A4Q36618526-5409173E-1957-44CF-84C7-FB49DCBD2B42Q36710199-E3E5B0E2-3C63-45B9-A0FD-471AD3388109Q36860987-F8C67316-4EAE-48FD-8058-A94C9F60529EQ36954710-3130AAF5-B261-4938-B7AF-14653427840CQ36967966-DDB30B0B-61E0-4628-B7F8-A981511B282FQ37201872-A7FED0FE-B46C-46D0-92F9-BE6204BDF764Q37270933-31C34293-24C0-42DC-8DB1-F29826601918Q37332412-F0466AE5-4664-4519-BD9F-829394CF8CE2Q37424820-4F72ACEE-BFD9-4868-944A-377A8C20EB64Q37435119-6E53B0DD-F231-4549-97E8-CBB49415556CQ37578047-CAA5E742-16CC-4ACF-B2F8-605AE50AD7C8Q37578050-3A63A8DF-053C-4044-8863-099A539CDCE2Q37670256-5B061AB3-2325-45FF-A300-72F2B64AB49AQ37825896-DA95015B-056D-4618-855F-E015305A1178Q37982663-70391523-6651-4AC8-854B-0A93CFB41D7BQ38013655-BBF55AB5-A175-40BE-9E03-E0619B987038Q38554818-D75C1621-F05A-4C9F-8FBB-7B50F577D9C3Q39188901-4CCF6008-CFB1-45B8-8E74-25984F84510DQ40582077-7DD5D6B4-DA1A-497D-ADD4-82D5C655648AQ40605771-BA988C53-040D-44F8-88CF-D1460D5336B5Q42488670-7274565D-03BB-4C8E-8DBB-1AE357A7B7A5Q43993807-8AEB2EFA-3C41-4C65-8E8C-2DB6B7C65ACAQ44359291-7B86DB00-DB37-4EEF-8EB3-9740B73E34BCQ44389411-04435FA4-3922-4D33-BEEB-D51B7A07E609Q47194100-B2E1DEEC-1023-43CA-920B-0AC78BA18132Q47400369-557E02BC-3421-48EE-B4C2-40F275744D77Q48368263-5186B809-CA74-4DC9-8A6A-4C78DEF16F70Q51739253-5B6F3F09-8C2F-41C8-AB0A-4E1EFE6023C1
P2860
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@en
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@nl
type
label
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@en
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@nl
prefLabel
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@en
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@nl
P2093
P2860
P356
P1476
Enhanced RANK ligand expressio ...... ls in Paget's disease of bone.
@en
P2093
D Anderson
F R Singer
G D Roodman
J M Bruder
N Kurihara
P2860
P304
P356
10.1172/JCI9133
P407
P577
2000-06-01T00:00:00Z